Free Trial

Hyperfine (HYPR) Competitors

Hyperfine logo
$1.08 -0.07 (-6.09%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.09 +0.01 (+1.02%)
As of 07/25/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HYPR vs. NYXH, DRTS, STIM, ZIMV, SMTI, BWAY, TCMD, CV, CVRX, and MGRM

Should you be buying Hyperfine stock or one of its competitors? The main competitors of Hyperfine include Nyxoah (NYXH), Alpha Tau Medical (DRTS), Neuronetics (STIM), ZimVie (ZIMV), Sanara MedTech (SMTI), Brainsway (BWAY), Tactile Systems Technology (TCMD), CapsoVision (CV), CVRx (CVRX), and Monogram Orthopaedics (MGRM). These companies are all part of the "medical equipment" industry.

Hyperfine vs. Its Competitors

Nyxoah (NASDAQ:NYXH) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

15.0% of Hyperfine shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 31.0% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nyxoah currently has a consensus price target of $14.50, indicating a potential upside of 91.29%. Hyperfine has a consensus price target of $1.06, indicating a potential downside of 1.85%. Given Nyxoah's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nyxoah is more favorable than Hyperfine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nyxoah
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hyperfine
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Hyperfine has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nyxoah$4.89M52.80-$64.10M-$2.13-3.56
Hyperfine$12.89M6.52-$40.72M-$0.54-2.00

Hyperfine has a net margin of -343.42% compared to Nyxoah's net margin of -1,571.39%. Nyxoah's return on equity of -63.37% beat Hyperfine's return on equity.

Company Net Margins Return on Equity Return on Assets
Nyxoah-1,571.39% -63.37% -46.67%
Hyperfine -343.42%-74.19%-62.40%

Nyxoah has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

In the previous week, Hyperfine had 2 more articles in the media than Nyxoah. MarketBeat recorded 3 mentions for Hyperfine and 1 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.87 beat Hyperfine's score of 0.97 indicating that Nyxoah is being referred to more favorably in the media.

Company Overall Sentiment
Nyxoah Very Positive
Hyperfine Positive

Summary

Nyxoah and Hyperfine tied by winning 8 of the 16 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Sign up to receive the latest news and ratings for HYPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HYPR vs. The Competition

MetricHyperfineMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$89.51M$6.85B$5.70B$9.50B
Dividend YieldN/A1.27%4.60%4.01%
P/E Ratio-2.0025.4528.1020.05
Price / Sales6.5264.09429.3789.38
Price / CashN/A20.5536.2258.56
Price / Book1.614.758.665.87
Net Income-$40.72M$176.14M$3.25B$258.55M
7 Day Performance17.38%2.92%4.22%3.73%
1 Month Performance47.70%3.23%10.51%11.75%
1 Year Performance-6.90%7.28%34.40%18.03%

Hyperfine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HYPR
Hyperfine
1.4288 of 5 stars
$1.08
-6.1%
$1.06
-1.9%
-6.1%$89.51M$12.89M-2.00190News Coverage
Positive News
Gap Up
NYXH
Nyxoah
2.523 of 5 stars
$7.94
-3.4%
$14.50
+82.6%
-10.6%$279.98M$4.89M-3.73110Positive News
DRTS
Alpha Tau Medical
2.8448 of 5 stars
$2.98
-2.0%
$8.00
+168.5%
+44.0%$257.85MN/A-6.4880
STIM
Neuronetics
1.4932 of 5 stars
$3.88
+6.0%
$5.50
+41.8%
+137.6%$241.98M$74.89M-2.96180Positive News
ZIMV
ZimVie
0.5308 of 5 stars
$18.76
+122.3%
$16.33
-12.9%
-13.8%$235.03M$449.75M-26.421,770News Coverage
Analyst Upgrade
High Trading Volume
SMTI
Sanara MedTech
2.0107 of 5 stars
$26.28
-0.1%
$49.50
+88.4%
-20.7%$233.84M$86.67M-19.6160Positive News
BWAY
Brainsway
2.7702 of 5 stars
$12.09
flat
$14.25
+17.9%
+53.3%$228.47M$41.02M60.45120Positive News
TCMD
Tactile Systems Technology
3.6431 of 5 stars
$9.66
+1.5%
$16.00
+65.6%
-18.3%$221.32M$292.98M14.641,037Positive News
CV
CapsoVision
N/A$4.45
-2.2%
N/AN/A$210.87MN/A0.0090Negative News
Gap Down
CVRX
CVRx
3.0268 of 5 stars
$8.29
+3.6%
$14.50
+74.9%
-12.5%$208.58M$51.29M-3.80160Positive News
MGRM
Monogram Orthopaedics
1.0841 of 5 stars
$5.69
+0.4%
$5.40
-5.1%
+126.3%$202.35M$370K-12.6428Gap Up

Related Companies and Tools


This page (NASDAQ:HYPR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners